MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge many intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Main trial aims ended up to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, although among the list of https://steeles999frc2.wikigop.com/user